Vitamin D supplementation was associated with modest improvements in knee symptoms over 5 years among patients with OA who did not undergo knee surgery.
Abatacept treatment was shown to lower RA disease activity, with the T2T approach associated with higher odds of achieving certain therapeutic endpoints.
REGULATED INFORMATION Following the in-principle agreement reached with its main creditors in the context of ongoing equity raise process, the focus of BioSenic is now to proceed with fundraising, allowing to start its phase 3 international clinical trial with oral arsenic trioxide (ATO) in the first-line treatment of chronic Graft-versus-Host-Disease (cGvHD). Mont-Saint-Guibert, Belgium, October 25, 2023, 7.00 am CEST – BioSenic provides third quarter 2023 Business Update Following the in-princ